Corrigendum: Anlotinib Combined with Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma

Jingzhen Shi,Ying-jie Zhang,Jin-zhi Wang,Jianbin Li,Zhenxiang Li

DOI: https://doi.org/10.3389/fonc.2020.583499

IF: 4.7

2020-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.00995.].

What problem does this paper attempt to address?

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan,Zhongzheng Zhu,Wei Mao,Hui Wang,Hong Qian,Jianguo Wu,Xianling Guo,Qing Xu

DOI: https://doi.org/10.3389/fonc.2021.796625

IF: 4.7

2022-01-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.683502.].

oncology
Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Xia Li,Xiufeng Yin,Huafeng Wang,Jiansong Huang,Mengxia Yu,Zhixin Ma,Chenying Li,Yile Zhou,Xiao Yan,ShuJuan Huang,Jie Jin

DOI: https://doi.org/10.18632/oncotarget.27310

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.14463.].
Corrigendum: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway

Xiaozhong Liao,Ying Gao,Jiahui Liu,Lan-Ting Tao,Dongmei Wang,Dan Xie,Sui‐Lin Mo

DOI: https://doi.org/10.3389/fonc.2021.670798

IF: 4.7

2021-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.01756/full.].
Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Wen-Jie Wu,Qian Liu,Pu-Gen An,Lin Wang,Jian-Yun Zhang,Yan Chen,Tong Zhang,Jie Zhang

DOI: https://doi.org/10.3389/fimmu.2023.1346845

IF: 7.3

2024-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1282629.].
Corrigendum: LCN2 Is a Potential Biomarker for Radioresistance and Recurrence in Nasopharyngeal Carcinoma

Meng-Xia Zhang,Li Wang,Lei Zeng,Zi-Wei Tu

DOI: https://doi.org/10.3389/fonc.2021.670714

IF: 4.7

2021-03-18

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.605777.].

oncology
Corrigendum: Hinokiflavone Inhibits Growth of Esophageal Squamous Cancer By Inducing Apoptosis via Regulation of the PI3K/AKT/mTOR Signaling Pathway

Jida Guo,Shengqiang Zhang,Jun Wang,Pengfei Zhang,Tong Lu,Linyou Zhang

DOI: https://doi.org/10.3389/fonc.2022.970020

IF: 4.7

2022-07-05

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.833719.].

oncology
Corrigendum: Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells Through Targeting CXCR4-STAT3 Pathway

Dongli Yue,Daiqun Zhang,Xiaojuan Shi,Shasha Liu,Anqi Li,Dong Wang,Guohui Qin,Yu Ping,Yamin Qiao,Xinfeng Chen,Feng Wang,Renyin Chen,Song Zhao,Lidong Wang,Yi Zhang

DOI: https://doi.org/10.3389/fonc.2022.860158

IF: 4.7

2022-02-24

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.00311.].

oncology
Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis

Yin Yang,Jianyang Wang,Wenqing Wang,Tao Zhang,Jingjing Zhao,Yu Wang,Yexiong Li,Luhua Wang,Nan Bi

DOI: https://doi.org/10.3389/fonc.2022.1007862

IF: 4.7

2022-08-24

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.810580.].

oncology
Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Xuan Wei,Juanjuan Shi,Qianhan Lin,Xiaoxue Ma,Yingxin Pang,Hongluan Mao,Rui Li,Wei Lu,Yu Wang,Peishu Liu

DOI: https://doi.org/10.3389/fonc.2021.742374

IF: 4.7

2021-09-07

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.642229.].

oncology
Erratum: [Corrigendum] Survival outcomes in patients with T3‑4aN0M0 glottic laryngeal squamous cell carcinoma and evaluation of postoperative radiotherapy.

Jian Zhou,Yu Heng,Yue Yang,Xiaoke Zhu,Liang Zhou,Hongli Gong,Chengzhi Xu,Lei Tao

DOI: https://doi.org/10.3892/ol.2024.14456

2024-01-01

Oncology Letters

Abstract:[This corrects the article DOI: 10.3892/ol.2022.13554.].
Corrigendum: TRPC1 Inhibits Cell Proliferation/Invasion and Is Predictive of a Better Prognosis of Esophageal Squamous Cell Carcinoma

Yun-Zhu Zeng,Yong-Qu Zhang,Jiong-Yu Chen,Li-Ying Zhang,Wen-Liang Gao,Xue-Qiong Lin,Shao-Min Huang,Fan Zhang,Xiao-Long Wei

DOI: https://doi.org/10.3389/fonc.2021.767805

IF: 4.7

2021-10-06

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.627713.].

oncology
Corrigendum: the Significance of Transarterial Chemo(embolization) Combined with Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

Qiao Ke,Fuli Xin,Huipeng Fang,Yongyi Zeng,Lei Wang,Jingfeng Liu

DOI: https://doi.org/10.3389/fimmu.2022.952446

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.913464.].
Corrigendum: Anticancer applications of phytochemicals in gastric cancer: effects and molecular mechanism

Zhaofeng Liang,Yumeng Xu,Yue Zhang,Xinyi Zhang,Jiajia Song,Hui Qian,Jianhua Jin

DOI: https://doi.org/10.3389/fphar.2024.1405513

2024-08-19

Abstract:[This corrects the article DOI: 10.3389/fphar.2022.1078090.].
Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Jianlin Xu,Haitang Yang,Bo Jin,Yuqing Lou,Yanwei Zhang,Xueyan Zhang,Hua Zhong,Huiming Wang,Dan Wu,Baohui Han

DOI: https://doi.org/10.1038/srep38270

IF: 4.6

2016-01-01

Scientific Reports

Abstract:Scientific Reports 6: Article number: 36371; published online: 04 November 2016; updated: 01 December 2016
Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Bi-Cheng Wang,Bo-Ya Xiao,Peng-Cheng Li,Bo-Hua Kuang,Wang-Bing Chen,Pin-Dong Li,Guo-He Lin,Quentin Liu

DOI: https://doi.org/10.1155/2021/3735726

IF: 4.501

2021-02-25

Journal of Oncology

Abstract:[This corrects the article DOI: 10.1155/2020/2368164.].

oncology
[Corrigendum] Combined antitumor effects of P‑5m octapeptide and 5‑fluorouracil on a murine model of H22 hepatoma ascites

Xiao Han,Liping An,Dongmei Yan,Hiroshi Matsuura,Weiguang Ding,Mengchuan Zhang,Guangyu Xu,Ying Sun,Guangxin Yuan,Manli Wang,Nanxi Zhao,Jingbo Sun,Xun Zhu,Peige Du

DOI: https://doi.org/10.3892/etm.2018.6971

IF: 2.7

2019-01-01

Experimental and Therapeutic Medicine

Abstract:[This corrects the article DOI: 10.3892/etm.2018.6422.].
Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

Lei Zhang,Zhi-Ping Yan,Zhong-Heng Hou,Peng Huang,Min-Jie Yang,Shuai Zhang,Shen Zhang,Shao-Hua Zhang,Xiao-Li Zhu,Cai-Fang Ni,Qiang Li

DOI: https://doi.org/10.3389/fmolb.2021.727969

IF: 6.113

2021-08-30

Frontiers in Molecular Biosciences

Abstract:[This corrects the article DOI: 10.3389/fmolb.2021.624366.].

biochemistry & molecular biology
Corrigendum: Brain Metastases from Esophageal Squamous Cell Carcinoma: Clinical Characteristics and Prognosis

Linlin Xiao,Yvonne M. Mowery,Brian G. Czito,Yajing Wu,Guangbin Gao,Chang Zhai,Jianing Wang,Jun Wang

DOI: https://doi.org/10.3389/fonc.2022.827810

IF: 4.7

2022-02-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.652509.].

oncology
Erratum: The clinical observation of acupuncture combined with antiemetic drugs in the prevention and treatment of CINV in breast cancer patients

DOI: https://doi.org/10.3389/fonc.2022.1058376

IF: 4.7

2022-10-13

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.888651.].

oncology
Corrigendum: Docetaxel-loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer

Xing Feng,Xiaoling Xiong,Shenglin Ma

DOI: https://doi.org/10.3389/fphar.2022.964540

IF: 5.6

2022-01-01

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2022.832725.].

Corrigendum: Anlotinib Combined with Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Corrigendum: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway

Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Corrigendum: LCN2 Is a Potential Biomarker for Radioresistance and Recurrence in Nasopharyngeal Carcinoma

Corrigendum: Hinokiflavone Inhibits Growth of Esophageal Squamous Cancer By Inducing Apoptosis via Regulation of the PI3K/AKT/mTOR Signaling Pathway

Corrigendum: Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells Through Targeting CXCR4-STAT3 Pathway

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis

Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Erratum: [Corrigendum] Survival outcomes in patients with T3‑4aN0M0 glottic laryngeal squamous cell carcinoma and evaluation of postoperative radiotherapy.

Corrigendum: TRPC1 Inhibits Cell Proliferation/Invasion and Is Predictive of a Better Prognosis of Esophageal Squamous Cell Carcinoma

Corrigendum: the Significance of Transarterial Chemo(embolization) Combined with Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

Corrigendum: Anticancer applications of phytochemicals in gastric cancer: effects and molecular mechanism

Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

[Corrigendum] Combined antitumor effects of P‑5m octapeptide and 5‑fluorouracil on a murine model of H22 hepatoma ascites

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

Corrigendum: Brain Metastases from Esophageal Squamous Cell Carcinoma: Clinical Characteristics and Prognosis

Erratum: The clinical observation of acupuncture combined with antiemetic drugs in the prevention and treatment of CINV in breast cancer patients

Corrigendum: Docetaxel-loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer